Letters sent to healthcare professionals in October 2016

A summary of recent safety letters sent to relevant healthcare professionals

From:
Medicines and Healthcare products Regulatory Agency
Published
8 November 2016
Therapeutic area:
Cancer, Endocrinology, diabetology and metabolism, Haematology and oncology, Respiratory disease and allergy and Urology and nephrology

In October 2016, the following letters were sent to relevant healthcare professionals:

  • Flolan (epoprostenol): (solvent pH 12) available from October 2016, with differences in storage and administration from previous formulation (pH 10.5)
  • Teva levothyroxine: reintroduction to market and introduction of new tablet strengths (letter for , and for ); see also further information here
  • Blincyto鈻� (blinatumomab):

Article citation: Drug Safety Update volume 10 issue 4, November 2016: 3.

Updates to this page

Published 8 November 2016

Related content